BioNTech’s Bold Vision Beyond Vaccines: A New Chapter in Cancer Therapy
BioNTech, renowned for its COVID-19 vaccine, is pivoting towards mRNA-based cancer treatments despite fiscal challenges. In 2024, earnings fell to €1.08 per share amid a strategic shift from COVID-19 vaccines…